摘要:
Novel peptides of the following formula (I): R1R2N-CHX-CO-A-B-D-E-(G)¿s?-K in which R?1, R2¿, A, B, D, E, G, K, X, and s have the meanings stated in the description, and the preparation thereof are described. The novel peptides have an antineoplastic effect.
摘要:
The present invention provides compounds of Formula (I), including pharmaceutically acceptable salts and/or prodrugs thereof, where G, Ra, R2, R3 are defined as described herein and their use as protein Kinase inhibitors.
摘要:
The present invention relates to polypeptides which comprise the ligand binding domain of Cdc25, crystalline forms of these polypeptides and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Cdc25. The invention also relates to the use of the three dimensional structure of the Cdc25 catalytic domain in methods of designing and/or identifying potential inhibitors of Cdc25 activity, for example, compounds which inhibit the binding of a native substrate to the Cdc25 catalytic domain.
摘要:
Compounds of formula (I) are disclosed, wherein R?1, R2, R3, and R4¿ have the meanings indicated in the description, as well as a process for the production of these compounds. The compounds are suitable for use as starting material for the synthesis of substances which have anti-tumour properties.
摘要:
Chemical compounds having structural formula (I) and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.
摘要:
The description relates to a process for producing pentapeptides of the formula (I) in which A and R1-R3 have the meanings given, in which the pentapeptide is constructed in steps from a prolinamide of the formula (II) in which R?1 and R2¿ have the meanings given above, and the group -NR1R2 may be hydrolytically separated from the peptide thus obtained.